glp·helper
glphelper.com/semaglutide/florida/jupiter
GLP-1 receptor agonistFDA-approved December 2017 (Ozempic) · June 2021 (Wegovy)Rx · Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)

Semaglutide® providers &
prescriptions in Jupiter, FL

Verified Semaglutide providers in Jupiter, FL. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

city providers
37
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Florida
38 of 38 shown

Find a Semaglutide provider in Florida.

Every entry is checked against the NPI registry and the Florida medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Florida city · /semaglutide/florida/{city}
§ 03Getting Semaglutide in Jupiter
38 providers · Jupiter, FL

How to get Semaglutide in Jupiter.

38 GLP-1 prescribers and 7 local resource types are on record for Jupiter, plus 3 nearby towns in the directory.

Prescribers in Jupiter
38 prescribers
38 GLP-1 prescribers in Jupiter, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (13), Family Medicine (12) and Internal Medicine (7). Any Florida-licensed physician, nurse practitioner, or PA can prescribe Semaglutide, over video or in person. The nearest towns on record are West Palm Beach (41 providers), Wellington (28 providers) and Boca Raton (42 providers).
Around the prescription in Jupiter
7 listed nearby
31 dietitians, 5 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Jupiter.
Medicaid (weight loss)
Diabetes only
As of April 2026, Florida Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Florida’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Ozempic, Rybelsus, and Wegovy. The brands differ in approved use and maximum dose.

Semaglutide is a once-weekly GLP-1 receptor agonist sold under three brand names by Novo Nordisk: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. The injectable forms share the same molecule; only the approved indication and maximum dose differ.[2][3]

In the STEP-1 obesity trial, adults without diabetes taking Wegovy (semaglutide 2.4 mg) lost a mean of 14.9% of body weight at 68 weeks versus 2.4% with placebo. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease but without diabetes.[1]

At a glanceMultiple (brand-specific)
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017 (Ozempic) · June 2021 (Wegovy)
Approved use
Type 2 diabetes (Ozempic/Rybelsus) · chronic weight management (Wegovy)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection (weekly) · oral tablet (Rybelsus, daily) · Once weekly (injectable)
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy

Community health · CDC

Weight & metabolic health in Jupiter

Jupiter, Florida has a population of 61,047 people. The adult obesity rate in Jupiter is an age-adjusted estimate of 23.8%, 5.8 percentage points below the Florida state rate of 29.6%. Diagnosed diabetes reaches 8.3% of adults in Jupiter. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 19.1% of adults in Jupiter.

of Jupiter adults have obesity
23.8%
diagnosed diabetes
8.3%
no regular physical activity
19.1%

Age-adjusted estimates for Jupiter, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshair shedding during weight loss
§ 05Support around Semaglutide in Jupiter
4 nutritionists

The prescription is one part. Here is the rest, in Jupiter.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Jupiter, FL, ordered as the registry lists them, never by who pays us.

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Christine Bandy, M.S.,R.D.,LD/N,CDE
NUTRITIONIST
Nutritionist
12300 Alternate A1A, 108
Call 561-371-8401NPI 1295765998
Debra Caramagno, A.P. , L.N
NUTRITIONIST
Nutritionist
4300 Us Highway 1
Call 561-775-3550NPI 1558396994
Brianna Davenport, HHP, NTP
NUTRITIONIST
Nutritionist
600 Heritage Dr Ste 210
Call 815-210-5888NPI 1164310199
Melissa Peters, DSC, MHNE
NUTRITIONIST
Nutritionist · Education
240 W Indiantown Rd Ste 102
Call 561-632-0478NPI 1184068397

Gyms near you

A gym gives you the regular movement that keeps muscle while the weight comes off.

Palm Beach Sports Club - Gardens
GYM
4.6 on Google · 616 reviews
4540 Donald Ross Rd
Website
Planet Fitness
GYM
4.5 on Google · 397 reviews
6707 W Indiantown Rd Unit 45B
Website
Loggerhead Fitness
GYM
4.8 on Google · 288 reviews
901 Donald Ross Rd
Website
MADabolic Jupiter
GYM
5.0 on Google · 278 reviews
901 W Indiantown Rd
Website
FitTown Jupiter
GYM
4.9 on Google · 247 reviews
1642 US-1
Website
CrossFit Sea Dog
GYM
5.0 on Google · 167 reviews
4300 U.S. Hwy 1 #212
Website
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the STEP weight-management program, the SUSTAIN diabetes program, and the SELECT cardiovascular outcomes trial. Figures are means at each trial's primary endpoint.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to semaglutide 2.4 mg or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide versus −2.4% with placebo; 86% of treated patients lost ≥5% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (Wegovy 2.4 mg)
−14.9%
STEP-1, 68 wk vs −2.4% placebo[2]
Patients losing ≥5% body weight
86%
STEP-1, 2.4 mg[2]
Major adverse cardiac events
−20%
SELECT, HR 0.80[3]
HbA1c reduction (T2D)
−1.4 to −1.8%
SUSTAIN program[4]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average semaglutide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
20 to 44%
mild
Most common; dose-dependent, usually eases after titration
Diarrhea
20 to 30%
mild
More frequent during dose escalation
Vomiting
16 to 24%
mild
Reduced by slower titration
Constipation
20 to 24%
mild
Abdominal pain
10%
moderate
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
1.6 to 2.6%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash, Wegovy (no insurance)
$1,300 to $1,400
per month
Brand-name retail average[6]
Cash, Ozempic (no insurance)
$950 to $1,150
per month
Brand-name retail average[6]
Commercial insurance (T2D)
$25 to $250
per month copay
Usually covered for diabetes with prior authorization
Commercial insurance (weight)
Often denied
Wegovy is on-label but frequently requires PA and is denied
Medicare Part D
$0 to $100
per month
T2D covered; weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $0 to $25
per month
Commercial insurance only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Semaglutide providers in Florida

NPI-verified Semaglutide (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Semaglutide in other states

Find NPI-verified Semaglutide (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Semaglutide in Florida

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is the active molecule in all three Novo Nordisk products. Ozempic and Rybelsus are approved for type 2 diabetes; Wegovy is approved for chronic weight management at a higher maximum dose (2.4 mg/week). Insurers treat the brands as separate drugs.[1]